A small study published online November 6 in Biology of Sport found broadly similar short-term recovery patterns after strenuous exercise among regular cannabis-and-tobacco co-users and comparison participants. The finding adds evidence to a specific sports-science question, but does not demonstrate that cannabis improves recovery or establish a safe dose for training.
The distinction matters for cannabis consumers who see recovery claims attached to workout products. Observing how existing users recover is different from giving a standardized cannabis product to randomly assigned participants and measuring its effects. This paper concerns the former question, with tobacco use adding another complication.
What the pilot study measured
Antoine Mendes and colleagues studied 26 physically active adults: 12 regular cannabis users and 14 non-users. The users predominantly consumed THC-dominant cannabis mixed with tobacco. Participants performed a drop-jump protocol, with muscle function, soreness and blood markers followed through 72 hours. The open-access paper is available through HAL; the journal record gives the November publication date and its 2027 issue citation.
The groups showed broadly similar concentric strength, muscle-damage marker and soreness responses. Some isometric strength differences appeared at individual time points. The authors identify a small sample, variable self-reported cannabis exposure and residual tobacco confounding as limitations. Acute and chronic cannabis effects could not be separated.
Those qualifications belong beside the result. A study of combined exposure cannot isolate a cannabis-only effect, and measurements over three days cannot establish what happens across months of training. Nor does an isolated difference on one strength measure justify describing cannabis as a recovery treatment.
The sample also comprised 20 men and six women, recruited as physically active students. That population limits how confidently the result can be extended to older adults, people managing injuries or elite competitors. The experiment did not compare every route of cannabis administration. A result involving habitual users of cannabis mixed with tobacco cannot simply be transferred to an edible, a vaporizer or a CBD-only topical.
Why similar results are not proof of a benefit
A finding of no clear difference answers a narrower question than a finding of equivalence. With a small group, uncertainty remains around effects that the experiment may not detect. Readers should therefore resist translating similar average patterns into a universal statement that cannabis has no consequences for every athlete.
The same restraint applies in the other direction. A statistically notable measurement is not automatically a meaningful improvement in sporting performance. Recovery, pain perception, strength and competition results are related ideas, but they are not interchangeable outcomes. This study cannot be used as a shortcut between them.
For a coach or recreational athlete, a useful reading starts with the population, exposure, comparison and follow-up. Ask who participated, what they actually used, whether exposure was controlled and what the researchers measured. Those questions reveal how far a headline can travel beyond the underlying experiment.
Recovery evidence does not settle training safety
The CDC’s cannabis and brain-health guidance describes effects on attention, coordination, movement and reaction time. It also notes that factors including THC concentration, frequency of use and other substances influence effects. Those considerations are separate from whether a particular muscle marker returns toward baseline after exercise.
That separation is practical. A laboratory recovery result does not tell someone whether they can safely handle equipment while impaired, drive home or make decisions during a demanding session. The paper should be read as research on measured recovery outcomes, rather than permission to disregard those other questions.
It is also distinct from a product efficacy claim. FDA’s cannabis guidance distinguishes approved medicines from unapproved products marketed with therapeutic claims. A published study is not itself FDA approval of a gummy, topical or recovery supplement, especially when the marketed product was never tested in that experiment.
Athletes have another rulebook to check
Drug-testing obligations remain a separate consideration. USADA’s advisory on the 2027 prohibited list says its changes take effect January 1, 2027. It describes in-competition restrictions on psychoactive cannabis components and compounds that mimic THC, while warning that CBD products can contain THC that creates a positive-test risk.
Those future rules should not be confused with the rules applicable before their effective date, and individual sports may operate under different policies. Athletes need to check the rules that govern their own competition rather than infer eligibility from a recovery paper or a product’s legal retail availability.
Our earlier explanation of the 2027 cannabis rulebook examines that distinction. This new study contributes a different piece of the discussion: limited human data on recovery, with uncertainties that remain essential to interpreting the result.
Illustrative gym stock photograph; not equipment or participants from the study. Photo: Hebert Santos / Pexels.